XRCC1 Polymorphisms are Associated with Cervical Cancer Risk and Response to Chemotherapy: a Systematic Review and Meta-analysis

  • Shuai, Han-Lin (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University) ;
  • Luo, Xin (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University) ;
  • Yan, Rui-Ling (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University) ;
  • Li, Jian (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University) ;
  • Chen, Dan-Liang (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University)
  • Published : 2012.12.31


Background: Functional single nucleotide polymorphisms of x-ray repair cross-complementing protein 1 (XRCC1) have been suspected to contribute to uterine cervical cancer risk for a long time; however, most previous case-control studies were small sized and biased. Additionally, recent studies suggested that XRCC1 polymorphisms could be a biomarker of response to platinum-based chemotherapy. Methods: A comprehensive search was conducted to retrieve eligible studies and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to measure association strength. Results: A total of 13 studies were identified and analyzed. We found that the Arg194Trp polymorphism (Trp vs. Arg, OR=1.342, 95% CI: 1.176) was associated with increased risk of cervical cancer, while no significant association was found with Arg280His (His vs. Arg, OR=1.059, 95% CI: 0.863, 1.299) or Arg399Gln (Gln vs. Arg, OR=1.144, 95% CI: 0.938, 1.394). As for response to platinum-based chemotherapy, the variant XRCC1 399Gln allele (Gln vs. Arg, OR=0.345, 95% CI: 0.163, 0.729) was linked with a poor response; however, the Arg194Trp polymorphism (TrpArg vs. ArgArg, OR=6.421, 95% CI: 1.573, 26.205) predicted a good response. Conclusion: The Arg194Trp polymorphism of XRCC1 increases risk of cervical cancer; the variant 399Gln allele predicts poor response to platinum-based chemotherapy, while the Arg194Trp polymorphism indicates a good response.


XRCC1;uterine cervical cancer;SNPs;susceptibility;chemotherapy response


Supported by : Guangdong Medical Science and Technology Research


  1. Barbisan G, Perez LO, Difranza L, et al (2011). XRCC1 Arg399Gln polymorphism and risk for cervical cancer development in Argentine women. Eur J Gynaecol Oncol, 32, 274-9.
  2. Cheng XD, Lu WG, Ye F, et al (2009). The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res, 28, 91.
  3. Chung, HH, Kim MK, Kim JW, et al (2006). XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol, 103, 1031-7.
  4. Dai L, Duan F, Wang P, et al (2012). XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 casecontrol studies. Mol Biol Rep, 39, 9535-7.
  5. Duell EJ, Wiencke JK, Cheng TJ, et al (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis, 21, 965-71.
  6. Duensing S, Munger K (2002). The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res, 62, 7075-82.
  7. Farkasova T, Gurska S, Witkovsky V, Gabelova A (2008). Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study. Neoplasma, 55, 330-7.
  8. Giuliano AR, Harris R, Sedjo RL, et al (2002). Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis, 186, 462-9.
  9. Hong-yu X, Wen-qing W, Hong-yan X, Xiao-Mei B (2010). Relationship between the polymorphism of XRCC1-Arg399Gln and incidence risk of cervical cancer in the population of Guangdong. Hainan Med J, 8, 35-7.
  10. Huang J, Ye F, Chen H, et al (2007). The nonsynonymous single nucleotide polymorphisms of DNA repair gene XRCC1 and susceptibility to the development of cervical carcinoma and high-risk human papillomavirus infection. Int J Gynecol Cancer, 17, 668-75.
  11. Kim K, Kang SB, Chung HH, et al (2008). XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinumbased neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol, 111, 509-15.
  12. Kornovski Y, Gorchev G (2006). Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB -IVA. J BUON, 11, 291-7.
  13. Li Y, Liu F, Tan SQ, et al (2012). X-ray repair crosscomplementing group 1 (XRCC1) genetic polymorphisms and cervical cancer risk: a huge systematic review and meta-analysis. PLoS One, 7, e44441.
  14. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
  15. Narter KF, Ergen A, Agachan B, et al (2009). Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res, 29, 1389-93.
  16. Niwa Y, Matsuo K, Ito H, et al (2005). Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecol Oncol, 99, 43-9.
  17. Przybylowska-Sygut K, Stanczyk M, Kusinska R, et al (2012). Association of the Arg194Trp and the Arg399Gln Polymorphisms of the XRCC1 Gene With Risk Occurrence and the Response to Adjuvant Therapy Among Polish Women With Breast Cancer. Clin Breast Cancer, 13, 61-8.
  18. Roszak A, Lianeri M, Jagodzinski PP (2011). Involvement of the XRCC1 Arg399Gln gene polymorphism in the development of cervical carcinoma. Int J Biol Markers, 26, 216-20.
  19. Sardi J, Sananes C, Giaroli A, et al (1993). Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol, 49, 156-65.
  20. Settheetham-Ishida W, Yuenyao P, Natphopsuk S, et al (2011). Genetic risk of DNA repair gene polymorphisms (XRCC1 and XRCC3) for high risk human papillomavirus negative cervical cancer in Northeast Thailand. Asian Pac J Cancer Prev, 12, 963-6.
  21. Sterne JA, Egger M (2001). Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol, 54, 1046-55.
  22. Taylor RM, Thistlethwaite A, Caldecott KW (2002). Central role for the XRCC1 BRCT I domain in mammalian DNA singlestrand break repair. Mol Cell Biol, 22, 2556-63.
  23. Tudek B (2007). Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med, 28, 258-75.
  24. Wang SS, Bratti MC, Rodriguez AC, et al (2009). Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis, 199, 20-30.
  25. Wen-peng M, Ping J, Yun G (2011). Single nucleotide polymorphisms of the DNA repair genes XPD and XRCC1 and the susceptibility to cervical squamous cell carcinoma. Progr Obster Gynecol, 881-5.
  26. Wen J, Mei-lin W, Zhi-zhong Z, et al (2008). The relationship between XRCC1 polymorphisms and the risk of cervical cancer in Jiangsu population. Acta Universitatis Medicinalis Nanjing(Natural Science), 1-6.
  27. Whitehouse CJ, Taylor RM, Thistlethwaite A, et al (2001). XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell, 104, 107-17.
  28. Wu J, Liu J, Zhou Y, et al (2012). Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res, 18, 3972-81.
  29. Wu MT, Liu CL, Ho CK, Wu TN (2004). Genetic polymorphism of p53 and XRCC1 in cervical intraepithelial neoplasm in Taiwanese women. J Formos Med Assoc, 103, 337-43.
  30. Xiao-qin W, Zhi-hui Y (2010). Relationship between XRCC1 polymorphisms and cervical cancer risk. Modern Med Health, 2137-38.
  31. Xue H, Ni P, Lin B, et al (2011). X-ray repair crosscomplementing group 1 (XRCC1) genetic polymorphisms and gastric cancer risk: A HuGE review and meta-analysis. Am J Epidemiol, 173, 363-75.
  32. Zhang L, Ruan Z, Hong Q, et al (2012). Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study. Oncology Letters, 3, 351-62.

Cited by

  1. Association of a miR-502-Binding Site Single Nucleotide Polymorphism in the 3'-Untranslated Region of SET8 and the TP53 Codon 72 Polymorphism with Cervical Cancer in the Chinese Population vol.15, pp.16, 2014,
  2. Stratification Analysis and Case-control Study of Relationships between Interleukin-6 Gene Polymorphisms and Cervical Cancer Risk in a Chinese Population vol.15, pp.17, 2014,
  3. XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis vol.35, pp.2, 2014,
  4. Three polymorphisms of DNA repair gene XRCC1 and the risk of glioma: a case–control study in northwest China vol.35, pp.2, 2014,
  5. Association between the p73 gene G4C14-to-A4T14 single nucleotide polymorphism and risk of cervical cancer by high resolution melting and PCR with confronting two-pair primers in a Chinese population vol.12, pp.1, 2016,